Related Experiment Video

Updated: Jun 9, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

793

Platelet Function, Platelet Size and Content of Reticulated Platelets: Interactions in Patients Receiving Dual

Valeria V Bodrova1, Olga N Shustova1, Nina V Golubeva1

  • 1Chazov National Medical Research Center of Cardiology, Russian Ministry of Health, 15a, Academician Chazov Str., Moscow 121552, Russia.

Cells
|October 25, 2024
PubMed

Insights

Platelet size and reticulated platelet (RP) content are linked to higher platelet activity. This association persists even with antiplatelet drugs, suggesting reduced treatment efficacy in cardiovascular patients.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Clinical Biochemistry

Background:

  • Increased platelet activity is a significant risk factor for thrombotic events in patients with cardiovascular diseases.
  • Understanding factors influencing platelet function is crucial for optimizing antiplatelet therapy.

Purpose of the Study:

  • To investigate the relationship between platelet function, platelet size, and reticulated platelet (RP) content in patients with coronary heart disease (CHD) and acute coronary syndrome (ACS).
  • To assess how these factors are affected by antiplatelet therapy (acetylsalicylic acid + clopidogrel or ticagrelor).

Main Methods:

  • Evaluated platelet function via activated glycoprotein (GP) IIb-IIIa and P-selectin exposure.
  • Assessed platelet size using mean volume, % large forms, and forward scattering.
  • Quantified reticulated platelets (RP) using thiazole orange staining in control and CHD/ACS patient groups.

Main Results:

  • In controls, activated GP IIb-IIIa and P-selectin correlated with platelet size and RP content.
  • These correlations were largely maintained in CHD/ACS patients despite reduced platelet activity due to antiplatelet drugs.
  • Specifically, activated GP IIb-IIIa showed persistent correlations with platelet size and RP content.

Conclusions:

  • Elevated platelet size and RP content are associated with heightened platelet activity.
  • These factors may indicate reduced efficacy of standard antiplatelet therapies in certain patient populations.
  • Platelet size and RP content serve as potential biomarkers for assessing antiplatelet therapy response.

Keywords:
P-selectinacetylsalicylic acidantiplatelet drugsclopidogrelglycoprotein IIb-IIIainterleukin 6platelet functionplatelet sizereticulated plateletsticagrelor

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

11.9K
Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.5K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
478
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.0K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.8K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
Coronary Artery Disease V: Surgical Management01:27

Coronary Artery Disease V: Surgical Management

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3